Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 9/20 | 0.39 |
| ▸ | CDK2 | P24941 | 9/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 2/20 | 0.35 |
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.34 |
| ▸ | PARP11 | Q9NR21 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31584234 | 0.91 | CCNA2 (0.38) | CCNA2CDK2PARP1 | |
| SCHEMBL24096427 | 0.84 | MKNK2 (0.43) | CCNA2CDK2PARP1 | |
| SCHEMBL30272102 | 0.84 | MKNK2 (0.43) | CCNA2CDK2PARP1 | |
| SCHEMBL19553162 | 0.79 | KDR (0.35) | PARP1 | |
| SCHEMBL21633640 | 0.79 | PARP10 (0.40) | GRM5CYP1A2OGAPARP1PARP10 | |
| SCHEMBL26440842 | 0.77 | CCNA2 (0.45) | CCNA2CDK2GRM5 | |
| SCHEMBL31584373 | 0.76 | PIM1 (0.33) | OGA | |
| SCHEMBL20779670 | 0.76 | GRM5 (0.38) | CCNA2CDK2GRM5CYP1A2OGA | |
| SCHEMBL951278 | 0.76 | CDC7 (0.50) | CCNA2CDK2 | |
| SCHEMBL23314219 | 0.75 | MAP4K1 (0.38) | GRM5CYP1A2OGAPARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025103367-A1 | LIGAND-DRUG CONJUGATE, LINKER FOR CONJUGATION, AND USE THEREOF | 海南先声再明医药股份有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4161928-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. Hoffmann-La Roche AG (CH) | 2023-04-12 | — | — | EP | disclosed |
| CN-115515960-A | Aminopyrimidine cyclic amides | 豪夫迈·罗氏有限公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021249904-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| WO-2021249904-A2 | AMINO-PYRIMIDINE CYCLO-AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
| EP-3359154-B1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2021-05-26 | — | — | EP | disclosed |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-02-13 | — | — | US | disclosed |
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2020-02-13 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| WO-2017062688-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) | 2017-04-13 | — | — | WO | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
| EP-2945623-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | Suzhou yunxuan yiyaokeji youxiangongsi (Su Zhou Yuan Pharm) (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014113191-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | ZHANG XIAOHU (CN) | 2014-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048223-A1 | WNT SIGNALING PATHWAY INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | WNT1, WNT3A, CTNNB1 | CCNA2 1554/4885CDK2 361/4885GRM5 3943/4885 |
| US-20230123268-A1 | AMINO-PYRIMIDINE CYCLO-AMIDES | ATXN2, ATXN2L, ATXN10 | CCNA2 36/4885CDK2 8/4885GRM5 1650/4885 |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | CCNA2 3162/4885CDK2 1488/4885GRM5 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.